Ovid Therapeutics Inc. (OVID) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
OVID currently has 187M outstanding shares. with significant dilution risk as 114M authorized shares could dilute existing holders by 61.3%. The company has significantly diluted shareholders by 127.25% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 186.6M shares outstanding |
190M | 110M |
| Mar 18, 2026 |
10-K filing | 131.9M shares outstanding |
130M | 170M |
| Mar 18, 2026 |
8-K filing: Ovid Therapeutics Inc. entered into a Securities Purchase Agreement to issue and sell 19,154,321 shares of common stock at $2.01 per share and pre-funded warrants to purchase up to 10,701,710 shares of common stock at $2.009 per Pre-Funded Warrant, with gross proceeds expected to be $60.0 million. ($60.0M proceeds) |
71M | 230M |
| Dec 15, 2025 |
S-3 filing: This prospectus relates to the offer and resale from time to time by the selling stockholders of up to an aggregate of 125,064,325 shares of our common stock. |
71M | 230M |
| Aug 13, 2025 |
10-Q filing | 71.1M shares outstanding |
71M | 100M |
| May 13, 2025 |
10-Q filing | 71.1M shares outstanding |
71M | 100M |
| Mar 11, 2025 |
10-K filing | 71.1M shares outstanding |
71M | 100M |
| Nov 12, 2024 |
10-Q filing | 71.0M shares outstanding |
71M | 110M |
| Aug 13, 2024 |
10-Q filing | 70.9M shares outstanding |
71M | 110M |
| May 14, 2024 |
10-Q filing | 70.7M shares outstanding |
71M | 110M |
| Mar 08, 2024 |
10-K filing | 70.6M shares outstanding |
71M | 110M |
| Dec 06, 2023 |
8-K filing: Jeremy Levin, CEO of Ovid Therapeutics Inc., gifted 1,146,500 shares of the company's common stock to family trusts; after the gift, Levin holds 3,598,467 shares. |
3.6M | 170M |
| Nov 03, 2023 |
10-Q filing | 70.6M shares outstanding |
71M | 110M |
| Nov 03, 2023 |
S-3 filing: The filing is an S-3 registration statement for the potential offering and sale of up to $250,000,000 of any combination of common stock, preferred stock, and debt securities. |
71M | 110M |
| Aug 04, 2023 |
10-Q filing | 70.5M shares outstanding |
71M | 35M |
| May 05, 2023 |
10-Q filing | 70.5M shares outstanding |
70M | 35M |
| Mar 13, 2023 |
10-K filing | 70.4M shares outstanding |
70M | 35M |
| Nov 08, 2022 |
10-Q filing | 70.4M shares outstanding |
70M | 35M |
| Aug 09, 2022 |
10-Q filing | 70.4M shares outstanding |
70M | 35M |
| May 10, 2022 |
10-Q filing | 70.3M shares outstanding |
70M | 35M |
| Mar 15, 2022 |
10-K filing | 68.1M shares outstanding |
68M | 38M |
| Jan 03, 2022 |
8-K filing: Ovid Therapeutics Inc. entered into a License Agreement with AstraZeneca AB, granting Ovid worldwide exclusive rights to develop and commercialize AstraZeneca's library of early-stage small molecules targeting the K+ Cl- co-transporter, including lead candidate OV350, with Ovid issuing 2,272,727 shares of its common stock to AstraZeneca. ($7.5M proceeds) |
68M | 38M |
| Nov 10, 2021 |
10-Q filing | 67.9M shares outstanding |
68M | 38M |
| Aug 16, 2021 |
10-Q filing | 67.8M shares outstanding |
68M | 38M |
| May 13, 2021 |
10-Q filing | 66.6M shares outstanding |
67M | 39M |
| Mar 15, 2021 |
10-K filing | 65.8M shares outstanding |
66M | 40M |
| Nov 13, 2020 |
S-3 filing: The company may offer up to $250,000,000 of any combination of common stock, preferred stock, debt securities and warrants. |
57M | 49M |
| Nov 13, 2020 |
10-Q filing | 63.4M shares outstanding |
63M | 42M |
| Aug 10, 2020 |
10-Q filing | 57.1M shares outstanding |
57M | 0 |
| May 07, 2020 |
10-Q filing | 54.8M shares outstanding |
55M | 0 |
| Mar 11, 2020 |
10-K filing | 54.7M shares outstanding |
55M | 0 |